Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
Megan M. Tu(University of Colorado Cancer Center), Dan Theodorescu(University of Arizona), Eric T. Clambey(University of Colorado Anschutz Medical Campus), Neeraj Agarwal(University of North Texas), Robert T. Jones(MedStar Franklin Square Medical Center), James C. Costello(University of Colorado Cancer Center), Alan J. Korman(Bristol-Myers Squibb (Germany)), Terry L. Ng(Ottawa Hospital), Erin Michaud(Bristol-Myers Squibb (United States)), Jason E. Duex(Cedars-Sinai Medical Center), Abigail K. Kimball(University of Colorado Anschutz Medical Campus), John C. Cambier(University of Denver), Jun Yan(Bristol-Myers Squibb (United States)), Brianne M. Coleman(University of Colorado Denver), Elizabeth Saravia(Bristol-Myers Squibb (United States)), Linda K. Johnson, Hany Abdel-Hafiz(University of Arizona), Francis Y. F. Lee(Bristol-Myers Squibb (United States)), Andrii I. Rozhok(University of Colorado Denver), Han Chang(Bristol-Myers Squibb (United States)), Krista Menard(Bristol-Myers Squibb (United States)), Robert F. Graziano(Bristol-Myers Squibb (United States)), Ana Chauca-Diaz(University of Colorado Anschutz Medical Campus)
Cited by 126
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k